The Science-Backed Bitter Compound That Mimics GLP-1 (No Injections Needed!) EAT LESS. FEEL FULL.

Kennedy emphasised that the onboarding is critical because the formulation 'super stimulates' the receptors, roughly doubling natural GLP-1 levels. Without it, the sudden CCK release can cause an uncomfortable laxative feeling. About 5% of users—likely those with 1-25 bitter receptor subtypes (super tasters)—only need one capsule, and the onboarding week helps individuals discover their personal threshold. She compared the effect to the body's natural signaling: the hormone curves mirror the body's own rhythm, just amplified, which is why the product doesn't cause constant high levels of GLP-1 (e.g., when sleeping). This on-demand mode of action is fundamentally different from injected GLP-1 agonists that bathe the body in the hormone around the clock.

Kennedy personally uses this approach: she takes a capsule at 9am and comfortably fasts until 1pm, noting that she eats less at lunch and doesn't experience rebound hunger later. She calls it a tool for 'lazy' intermittent fasters, meaning it reduces the willpower required. The capsule's 4-hour action window covers the typical pre-lunch hunger peak, and because it follows the body's own rhythm, it does not interfere with the natural nighttime dip in GLP-1.

Kennedy described using it during a trip to the US where airport food and restaurants were constant temptations, and she found it helped her make better choices without feeling restricted. She also uses it before a cocktail party to avoid overeating canapés. The flexibility is a key differentiator from daily drugs; she can skip it for a special dinner and still feel in control. This approach normalises the tool as a 'safety net' rather than a chronic medication.

Kennedy noted that many women don't realise their monthly cravings are biologically driven (progesterone-induced increase in BMR and hunger) and often blame themselves. Calocurb offers a cycle-synced intervention that can be taken only when needed, avoiding the mindset of a chronic drug. Practitioners can prescribe it as a 'rescue' protocol for the 10-14 days before menstruation, potentially breaking the cycle of PMS-related bingeing.

Kara Fitzgerald mentioned she has used it in her practice exactly for this purpose, citing an example of a patient on an elimination diet who was unhappy about the restrictions but found Calocurb helpful. Kennedy endorsed this, saying the product is a 'tool in the toolkit' and that practitioners are best placed to combine it with dietary and behavioural management. This positions Calocurb as a bridge that helps patients stick with difficult dietary changes long enough to see benefits, after which the new habits may become self-sustaining.

Kennedy argued this is the most important use case, calling it 'a must' rather than an 'if'. She pointed to a paper showing that all patients felt fear and hopelessness when coming off the drugs, compounding the physiological hunger with psychological distress. By introducing Calocurb during the taper, patients maintain some food-noise reduction, giving them the psychological space to develop new habits without the abrupt shock of zero support. She is now designing a clinical trial specifically for this maintenance/transition population. This protocol has already been adopted by some functional-medicine clinicians, who report that it allows them to keep patients on the lowest possible GLP-1 dose while still achieving results.

Dr. Kennedy explained that the team's hypothesis grew from historical observations that bitter plants were chewed to suppress appetite during famines, and from animal data. By proving that bitter receptors are densely present along the GI tract, they established a direct chemical-sensing link between what we eat and the release of satiety hormones. The mapping showed that humans evolved with these receptors as a defense against poisoning: if bitter (potentially toxic) substances reach the intestine, the body releases hormones that tell the brain to stop eating, because vomiting or ghrelin-driven dissipation are no longer possible at that stage. This evolutionary logic was the bedrock for screening for a safe, food-grade bitter agonist that could trigger the same pathway without toxicity.

After mapping the receptors, the researchers built a high-throughput intestinal-cell model and tested over 1000 plant extracts. Only two activated the hormone release: a potato oxalate (poisonous) and a hop extract. They then screened 50 New Zealand hop varieties to find the one with the highest expression of appetite-suppressing hormones, naming it 'Eureka'. The active extract, Amarasate, is a CO₂ supercritical extract that removes phytoestrogens, leaving alpha and beta acids and a small essential oil fraction. Kennedy stressed that the spike above 400% is essential—below that, hormone changes do not translate into a person feeling full and eating less. This is why many products that claim to 'stimulate GLP-1' fail to produce meaningful behavioral change.

At the end of 24 hours, women on Calocurb were no hungrier than they had been at 16 hours (100% decrease in hunger), while the placebo group was ravenous. Craving decreased by an additional 120%—a massive effect that Kennedy attributes to the product's ability to silence food noise. Rebound eating, measured 4 hours after the last dose, showed a 12% calorie reduction, confirming the duration of action extends well beyond the immediate post-dose window. She pointed out that in the luteal phase women naturally eat ~200 extra calories per day; being able to take the capsule only during that window (since it's not a daily drug) offers a precision tool for practitioners.

Kennedy insists that using Calocurb during tapering is 'not an if, it's a must' because the exogenous hormone shuts down the body's natural production. By stimulating the bitter taste receptors in the gut, Calocurb super-stimulates endogenous GLP-1, CCK, and PYY, rebuilding the pathway. This also helps patients psychologically, as they transition from the 'no food noise' of the drug to a manageable state, letting them learn new eating behaviors without the crash. She is planning a dedicated clinical trial to study this maintenance protocol, and in practice many clinicians already use it to reduce the injectable dose to the minimum effective level.

Kennedy says the product acts as 'my little helper', reducing the volume of hunger signaling so she can walk past muffins and bagels without struggle. She uses it flexibly—a morning capsule to sustain intermittent fasting until 1 pm, an afternoon capsule before an evening event, or skips it when she wants to fully enjoy a special meal. She calls it a 'safety net' that she can step in and out of, which is why many long-term users continue for years. This personal narrative is central to why she commercialized the discovery, and she frames Calocurb not as a drug but as a tool to support the behavioral and dietary strategies practitioners already prescribe.